QMS Medical Allied Services Announces 9th AGM on Sep 30, 2026; Recommends Dividend
QMS Medical Allied Services will hold its 9th AGM on September 30, 2026, to adopt FY26 financial statements and recommend a dividend of ₹0.50 per share. The AGM will also approve the appointment of Mr. Pranav Manhar Badheka as an Independent Director and related party transactions up to ₹20 crore with its subsidiary.
The AGM, dividend recommendation, director appointments, and related party transactions are material corporate events that can impact investor perception and company operations.
The announcement is routine and concerns the AGM, financial statement presentation, director appointments, dividend recommendation, and related party transactions, which are standard corporate actions. It does not contain significantly positive or negative news.
QMS Medical Allied Services Limited has announced that its 9th Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 2:30 p.m. IST, through Video Conferencing or Other Audio Visual Means. The company will present the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026. The AGM will also consider the re-appointment of Mr. Mahesh Pahalraj Makhija as Managing Director, who retires by rotation. Additionally, the appointment of Mr. Pranav Manhar Badheka as an Additional Non-Executive Independent Director, effective from September 03, 2026, for a term of five years until September 02, 2031, will be regularized. A final dividend of ₹0.50 per equity share (5%) for FY 2025-26 is recommended, subject to member approval. The company also seeks approval for material related party transactions with its subsidiary, Saarathi Healthcare Private Limited, not exceeding ₹20 crore. The Annual Report for FY 2025-26 has been enclosed and will be available on the company's website.
What to do with a filing like this
QMS Medical Allied Services Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by QMS Medical Allied Services Limited. Read the original for the full detail.